Skip to main content
. Author manuscript; available in PMC: 2018 Aug 17.
Published in final edited form as: Cond Med. 2018 Feb 15;1(2):57–63.

Figure 5.

Figure 5

Primary cultured WT mouse astrocytes were pretreated with PD98059 (20 μM) an inhibitor of p44/42 MAPK, or vehicle for 30 min before 24 hours thrombin (0.5 U/ml) treatment (TPC). Astrocytes were then exposed to OGD for 3 h and (A) LDH levels and (B) the % of dead cells were measured after 24 h of reoxygenation. (C) Other astrocytes were collected after the 24 hours of thrombin treatment to assess immunoreactivity and protein levels (Western blot) of total (T-) and phosphorylated (P-)p90RSK (T359/S363) and HSP25. Values are mean ± SD, for control (0 U/ml thrombin), TPC+ vehicle and TPC + PD98059 groups. *p<0.05, #p<0.01 indicate TPC+vehicle vs. the other groups. Scale bar = 50 μm.